Phaseline

Companies › Estar Medical dba Medical Technologies

Estar Medical dba Medical Technologies: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Metabolic and endocrine.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Tropocells(R) Autologous Platelet-Rich Fibrin (PRF)
Autologous platelet-rich fibrin for wound healing
–Phase 2Diabetic Foot Ulcer–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06810726Tropocells(R) Autologous Platelet-Rich Fibrin (PRF)Phase 2Diabetic Foot UlcerMetabolic and endocrineMay 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Wellizen Australia AB Biotics Immunis Spur Therapeutics iECURE

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.